This stock is up $2 billion dollars overnight on an earnings beat of $10 million dollars. That is a P/E ration of 200, Parabolic and unbridled enthusiasm is for soccer moms who open a trading account at the end of a bull market. Congrats to the long players. Pigs get fat....and hogs, well---maybe you know or don't know.
I just see people being people...optimistic and pessimistic, argumentative and agreeable...pi**ssed off and less than that...but not by much.
yes, at the time, i had anticipated a positive ruling from the ema in january...then i had expected revenues to come in over the following quarterly earnings reports. Since then, investors have endured no less than 3 clockstops and another one coming. Back then I was clearly optimistic on the future of the company, but one can only be fooled so many times. Clinuvel now owns the dubious honor of having the second longest ongoing review in the history of the EMA. It is moving well into territory of being the longest review in the history of the EMA. If that doesn't take the air out of anyone's optimism for the future of this company then I don't know what does. I love the potential of the company's drug candidate...I always have. It is becoming increasingly difficult and desperate to love the potential future of Clinuvel with so many strikes against it. The lack of significant funding in the coffers and the clearly apparent animosity towards it from the medical regulatory agencies spell out the very high probability of a dismal future and a bitter end to this company. I'm keeping my holdings and considering it a total loss unless something miraculous happens. It's not looking good any way you slice it. You seem to have nothing else to live for than chastising any negativity towards this company, and it seems that you have nothing better to do with your time than hone your disparaging remarks towards any naysayers. Good luck with your healthy endeavors there Poo.
Poo..I'll give you 50k shares @ $10/sh...surely that would be a shrewd investment since this will be well north of $100/sh in 18 months...wait, we've been hearing those prognostications since 2010. Maybe this will be the next Vertex....that stock gained $10 billion in market cap in a single day based on a 64 percent decline in Quarterly revenue growth and the hope for a minute cystic fibrosis patient population. Their drug is favorable to 4 percent of afflicted patients. This company is hard pressed to gain $10 million in market cap on any given year. No love here for sure.
looks like we might be waiting until xmas time for the next review / rejection. Looking for a miracle here...never happens, but there is always hope.Sell all you can to Poo and buy back at half price come september. Some of the board members on the EMA clearly have an agenda and do not want Clinuvel to succeed on even the smallest merit it appears.
Americans aren't banned from the Sharescene forum...just posters that have nothing tangible to say are. Your posts are one brazen attack after another...you never provide input and only provide insults. Who wants that? Whether the contributions are right or wrong, at least they pertain to the company in question and aren't directed towards quantifying the intentions of other posters.
your curiosity seems to be limited to disagreeable posts in whatever forum you view. You do not engage in any dialogue other than to attack viewpoints or posters that you can't seem to stomach. I can now see why you were kicked off Sharescene, and most likely any high school debate team you tried to participate in. The best or worst posts in the world will not influence the share price of even a thinly traded stock in the long run. I can't even fathom that you believe such foolishness. I don't have an agenda, never did. I grumble about this stock when disappointment sets in...which seems to be every 3-6 months. Someday, something good may happen...until then, this is a severely speculative play that has only incurred magnificent losses for 99 percent of the clinuvel investing community.
dude, I'm here for the big money...EPP is only a orphan drug market...there is no money there. All of Europe represents 700 million people. All of the United States represents 300 million people. This is a combined 1 billion people. the global population is 7 billion people. 1/7 th is just over 14 percent. If there are 10,000 estimated global sufferers with EPP, then it makes perfectly reasonable sense that the addressable markets for the EMA and FDA combined approval is 1400 persons. No drug has 100 percent adoption...an extremely high rate, an almost unattainable adoption rate would be 50 percent. This leaves 700 candidates for EPP. Even if the ridiculous $32k a year estimate was achieved, this would be $22 mill a year in gross revenues. My realistic guess is that this number is reduced to $5k/yr per patient. leaving $3.5 mill/yr in gross revs Assuming the average profit margin for major pharmaceutical companies of $18.4 percent, then $4 million profit is the highest possible windfall annually with these astronomical estimates (32k/yr per patient). This won't happen with EPP. EPP will lose money. Vitiligo is the only addressable clinical market that contains enough population to make substantial money. EPP must be approved before vitiligo treatment has an opportunity to succeed. I am all for EPP, but the sooner the better, because this will pave the way for Vitiligo. The longer we are in limbo, the worse it gets. Do you know how ridiculous and crazy you sound attacking other posters and accusing them of working in a boiler room for a short side hedge fund? Please dude, chill out before you stroke out and die clutching worthless clinuvel certificates in your white knuckled hands.
simply a matter of gross margins...besides, vips has 10 times the market cap of dang, so I believe the higher margins of vips is securely represented in their current stock price.
i do think that mgmt is performing admirably and have done all they can in what appears to be a challenging regulatory environment. My beef stems from the constant delays which are the direct result of the EMA. The shareholders and officers of Clinuvel appear to bear the brunt of these setbacks through capital raisings, share dilution, and missed deadline after missed deadline. Patience is thin, so I'll relegate myself to a few blogged gripes and groans then wait some more.
don't forget to add that the share count has been diluted with an additional 4.4 million shares or 12 percent of the total value of the company. I will wait for the end of June to hear the delay and then sit back and wait for the next development or disappointment...or whatever this company's track record is good at. I'm not a cheerleader of bi-annual capital raisings and share dilution several years in a row after the previous overly diluted share count of 300 million was reverse split 10:1 to go back down to 30 million. Every 6 months I hear some more poster talk about how good it is to get more money. Please stop.
trading halt until wednesday while a capital raising is performed. If Clinuvel believed the outcome would be positive, then they would most likely wait until after the decision and the share price appreciating. This is a sure sign of a white flag and accepting either a negative decision or another delay. This is by far the most brutal company I have invested in. They seem to be doing all they can and the EMA keeps hosing them. At this rate, the FDA will make a decision before the EMA. GL
shows a brain dead vegetable in the hospital. Egads! With the exception of a 3 month flash up in the frying pan, this company has been dead money. $5 seems to be the floor, but even 1 percent interest in a money market pays off better than TNAV. Who knows, maybe this takes off again sometime over the next couple years, stranger things have happened for sure. GL
never ever buy a stock with billions of shares. This one is a chart topper with 6 billion shares outstanding. It would take unprecedented volume to move the needle on this stock.
p/s of 27 is ludicrous. The market cap is staggering for a company that loses money and maintains meager revenues on a comparative scale. I personally like the company, but hate the price. This is a $15-$20 stock at best.
anyone touting an overpriced $4 biilion company that loses money as a $40 billion company should be examined by a criminal psychologist. $600 million in revenue currently means this would have to grow to $14 billion in revenue for a modest p/s ratio that reflects industry standards. Einhorn may be overestimating his short, but if anything, the company is way overvalued, not undervalued.